NEW YORK (GenomeWeb) – The New York State Department of Health has approved BioTheranostics to offer its Breast Cancer Index to residents in the state, the company said today.
The molecular diagnostic test quantifies the risk of recurrence of early stage, estrogen receptor-positive breast cancer. According to the San Diego firm, it is the only commercially available biomarker for estrogen receptor-positive breast cancer patients that accurately predicts early and late distant recurrence of the disease while also predicting the benefit from extended endocrine therapy.
Last week, the company announced a contract with preferred provider organization FedMed to provide coverage of BioTheranostics' tests for breast cancer and metastatic cancers.